Q2 FY27 results analysis · October 30, 2026
General Insurance Corporation of India (GICRE) Q2 FY27 Results Analysis: PAT Falls 14%, Claims Jump 54%
−14.3%PAT year on year, Rs. 2,455.62 Cr
Source: Quarterly results filing (BSE)
Quick summary
General Insurance Corporation of India's Q2 FY27 numbers came in mixed, with revenue of Rs. 13,469.45 Cr (+13.85% YoY) and PAT growth of -14.34% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details
| Results date | October 30, 2026 |
|---|---|
| Revenue (Q2) | Rs. 13,469.45 Cr (+13.85% YoY) |
| PAT (Q2) | Rs. 2,455.62 Cr (-14.34% YoY) |
| EPS (Q2) | Rs. 14.00 (-14.32% YoY) |
Quarter Snapshot
GIC Re delivered 16.94% YoY standalone GPW growth, ahead of its ~10% FY27 target, and consolidated PAT rose 9.16% YoY with the combined ratio improving to 106.01%. However, standalone underwriting losses widened to Rs.1,079.65 Cr on a 53.55% YoY jump in outstanding claims and health-segment deterioration, pushing PAT down 14.34% YoY. Growth is on track but the profitability leg toward the domestic 103 combined ratio target remains unproven on disclosed evidence.
Q2 FY27 Expectations vs Results
| Driver | What happened | Verdict |
|---|---|---|
| GPW in-line to ahead: "industry GDPI base … +9.58% cumulative through August … a tailwind for GPW even on the seasonally light Q2 base" | SA GPW +16.94% YoY; H1 +12.34% — ahead | Played out |
| Claims pressure: "the Rs.440 Cr Gujarat IBNR booked at Q1 can develop further in Q2" | Incurred claim ratio 87.39% (vs 85.04% Q1); change in O/S claims +53.55% YoY; Q2 cat quantum not disclosed — direction confirmed, not quantified in filing | Partially |
| "investment income is the most likely line to land behind YoY" vs the Rs.3,791.67 Cr Q2 FY26 presentation-basis base | Filing-basis investment income +10.70% YoY (Rs.2,815.31 Cr); note the pre-call note itself flagged the definitional gap between the filing's narrower net line and the presentation's gross figure — on the filing's own… | Contradicted |
| Follow-up on the Q1 subsidiary drag ("consolidated PAT below standalone") | Reversed: consolidated PAT Rs.2,945.13 Cr > standalone Rs.2,455.62 Cr (+Rs.489.51 Cr); associates now the drag (Rs.20.56 Cr, −88.29% YoY) — in the favorable direction | Contradicted |
| "solvency gliding down gradually from ~4.3" | 4.32 → 4.18 | Played out |
| "the Gujarat cat development inside Q2 is the direct test of the 103 domestic target" | Domestic/foreign CR split not disclosed; blended standalone 110.23% Q2 / 107.39% H1 — not observable at required granularity | Partially |
| Whether the Q1 overseas ~95-level result "is repeating or was transient" | Consolidated underwriting loss narrowed to Rs.(611.21) Cr from Rs.(1,133.16) Cr in Q1; consolidated combined ratio improved to 106.01%; geographic CRs not disclosed | Partially |
Read our full results preview.
Management Guidance vs Delivery
| What management said | What happened | Verdict |
|---|---|---|
| Overall premium growth ~10% FY27 | H1 GPW +12.34% YoY; Q2 +16.94% | On Track |
| Domestic book combined ratio 103 (FY27) | Geographic split not disclosed; blended standalone combined ratio 107.39% H1, 110.23% in Q2 — blended level above target, split unobservable | Too Early |
| Solvency glide-down, gradual from ~4.3 | 4.32 → 4.18 | On Track |
| "Profitability will be the driving factor as compared to the growth" (Q1 FY27 call) | Q2 GPW +16.94% YoY but standalone underwriting loss widened to Rs.(1,079.65) Cr and combined ratio rose to 110.23% vs 108.45% YoY — consolidated combined ratio did improve YoY: 106.01% vs 110.58% | Contradicted on the standalone book this quarter |
| "Investment income remains a meaningful contributor to overall profitability" (management commentary) | Investment income +10.70% YoY standalone; yield 12.92% without unrealized gains vs 9.47% in Q1 | Confirmed |
| "Quarterly performance is not strictly indicative of full-year results" (filing note) | Q2 is the seasonally light quarter; H1 blended combined ratio 107.39% is ~flat YoY (107.41%) | Confirmed as caution; H1 is the cleaner read |
Key Numbers, Quarter by Quarter
| Metric | Q2 FY26 | Q1 FY27 | Q2 FY27 | H1 FY27 | H1 FY26 | FY26 |
|---|---|---|---|---|---|---|
| Combined ratio % | 108.45 | 104.88 | 110.23 | 107.39 | 107.41 | 106.02 |
| Adjusted CR % | 79.09 | 87.73 | 83.58 | 85.92 | 83.74 | 84.79 |
| Incurred claim ratio % | 81.51 | 85.04 | 87.39 | 86.19 | 86.45 | 85.40 |
| Net retention % | 90.23 | 93.98 | 94.07 | 94.02 | 92.31 | 92.19 |
| Solvency x | 3.85 | 4.32 | 4.18 | 4.18 | 3.85 | 4.21 |
| EoM ratio % | 1.13 | 0.99 | 1.04 | 1.01 | 0.84 | 0.97 |
Key Investment Insights
Key Positives
- Standalone GPW grew 16.94% YoY to Rs.11,228.21 Cr; H1 GPW up 12.34% YoY, tracking ahead of the ~10% FY27 target
- Consolidated PAT rose 9.16% YoY to Rs.2,945.13 Cr, exceeding standalone PAT by Rs.489.51 Cr, reversing the Q1 subsidiary drag of Rs.302.90 Cr
- Consolidated combined ratio improved to 106.01% from 110.58% a year ago
- Investment income grew 10.70% YoY to Rs.2,815.31 Cr with yield of 12.92% without unrealized gains
- Life segment swung to underwriting profit of Rs.123.50 Cr from a loss of Rs.123.12 Cr a year ago
- Fire segment underwriting result of Rs.95.77 Cr vs a loss of Rs.26.33 Cr a year ago
- Solvency ratio of 4.18 vs 3.85 a year ago; gross/net NPAs at 0.94%, down from 1.06% a year ago
- Consolidated H1 CFO of Rs.2,384.95 Cr vs −Rs.206.41 Cr a year ago
Risk Factors
- Standalone underwriting loss widened to Rs.1,079.65 Cr from Rs.690.00 Cr YoY; combined ratio rose to 110.23% from 108.45%
- Change in outstanding claims (incl. IBNR/IBNER) rose 53.55% YoY to Rs.2,965.20 Cr, driving margin deterioration
- Health segment underwriting result swung from +Rs.129.62 Cr to −Rs.450.84 Cr YoY despite net premium growth of 52.47%
- Standalone PAT fell 14.34% YoY; effective tax rate rose to 20.82% from 17.45%
- FX gain shrank to Rs.94.45 Cr from Rs.363.18 Cr, a Rs.268.73 Cr negative swing
- Associates' contribution fell 88.29% YoY to Rs.20.56 Cr, capping consolidated profit growth at 3.21%
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Companies on this page
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.